{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:39:19Z","timestamp":1782391159211,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA225617"],"award-info":[{"award-number":["T32CA225617"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00198-022-06458-z","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T02:02:44Z","timestamp":1655172164000},"page":"1989-1997","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The impact of bone mineral density screening on incident fractures and healthcare resource utilization among postmenopausal breast cancer survivors treated with aromatase inhibitors"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9013-2469","authenticated-orcid":false,"given":"S.","family":"Bailey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mhango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,14]]},"reference":[{"key":"6458_CR1","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/1055-9965.EPI-16-0889","volume":"26","author":"AB Mariotto","year":"2017","unstructured":"Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M (2017) Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Prev Biomarkers 26:809\u2013815","journal-title":"Cancer Epidemiol Prev Biomarkers"},{"key":"6458_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71\u201396","journal-title":"CA Cancer J Clin"},{"key":"6458_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD et al (2016) Cancer treatment and survivorship statistics, 2016. Ca Cancer J Clin 66:271\u2013289","journal-title":"Ca Cancer J Clin"},{"key":"6458_CR4","first-page":"1029","volume":"20","author":"EA Perez","year":"2006","unstructured":"Perez EA, Serene M, Durling FC, Weilbaecher K (2006) Aromatase inhibitors and bone loss. Oncology (Williston Park, NY) 20:1029","journal-title":"Oncology (Williston Park, NY)"},{"key":"6458_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.18.01160","volume":"37","author":"HJ Burstein","year":"2019","unstructured":"Burstein HJ et al (2019) Adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 37:423\u2013438","journal-title":"J Clin Oncol"},{"key":"6458_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.steroids.2014.12.010","volume":"99","author":"JA Cauley","year":"2015","unstructured":"Cauley JA (2015) Estrogen and bone health in men and women. Steroids 99:11\u201315","journal-title":"Steroids"},{"key":"6458_CR7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","volume":"11","author":"JR Gralow","year":"2013","unstructured":"Gralow JR et al (2013) NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw 11:S1\u2013S50","journal-title":"J Natl Compr Canc Netw"},{"key":"6458_CR8","doi-asserted-by":"crossref","unstructured":"Shapiro, CL. et al. (2019) Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol JCO-19.","DOI":"10.1200\/JOP.19.00427"},{"key":"6458_CR9","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.1200\/JOP.2016.018341","volume":"13","author":"J Stratton","year":"2017","unstructured":"Stratton J et al (2017) Bone density screening in postmenopausal women with early-stage breast cancer treated with aromatase inhibitors. J Oncol Pract 13:e505\u2013e515","journal-title":"J Oncol Pract"},{"key":"6458_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1089\/jwh.2012.3687","volume":"22","author":"L Spangler","year":"2013","unstructured":"Spangler L, Yu O, Loggers E, Boudreau DM (2013) Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors. J Women\u2019s Health 22:132\u2013140","journal-title":"J Women\u2019s Health"},{"key":"6458_CR11","doi-asserted-by":"publisher","unstructured":"Shapiro, CL. cancers Osteoporosis: a long-term and late-effect of breast cancer treatments. https:\/\/doi.org\/10.3390\/cancers12113094.","DOI":"10.3390\/cancers12113094"},{"key":"6458_CR12","doi-asserted-by":"publisher","unstructured":"Colzani, E. et al. (2016) Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. https:\/\/doi.org\/10.1038\/bjc.2016.314","DOI":"10.1038\/bjc.2016.314"},{"key":"6458_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/jbmr.4250","volume":"36","author":"H Lu","year":"2021","unstructured":"Lu H et al (2021) Bone mineral density at the time of initiating aromatase inhibitor therapy is associated with decreased fractures in women with breast cancer. J Bone Miner Res 36:861\u2013871","journal-title":"J Bone Miner Res"},{"key":"6458_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.semcancer.2012.03.006","volume":"22","author":"D Spano","year":"2012","unstructured":"Spano D, Heck C, de Antonellis P, Christofori G, Zollo M (2012) Molecular networks that regulate cancer metastasis. In Seminars in cancer biology 22:234\u2013249","journal-title":"In Seminars in cancer biology"},{"key":"6458_CR15","doi-asserted-by":"publisher","first-page":"e190429","DOI":"10.1001\/jamanetworkopen.2019.0429","volume":"2","author":"H-M Chen","year":"2019","unstructured":"Chen H-M, Chen F-P, Yang K-C, Yuan S-S (2019) Association of bone metastasis with early-stage breast cancer in women with and without precancer osteoporosis according to osteoporosis therapy status. JAMA Netw Open 2:e190429\u2013e190429","journal-title":"JAMA Netw Open"},{"key":"6458_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1759720X14546350","volume":"6","author":"K Panday","year":"2014","unstructured":"Panday K, Gona A, Humphrey MB (2014) Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskeletal Dis 6:185\u2013202","journal-title":"Ther Adv Musculoskeletal Dis"},{"key":"6458_CR17","unstructured":"Stedman MR, Doria-Rose P, Warren JL, Klabunde CN & Mariotto A. Comorbidity technical report the impact of different SEER-medicare claims-based comorbidity indexes on predicting non-cancer mortality for cancer patients for more information."},{"key":"6458_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1604700","volume":"375","author":"PE Goss","year":"2016","unstructured":"Goss PE et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375:209\u2013219","journal-title":"N Engl J Med"},{"key":"6458_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.21037\/gs.2018.07.05","volume":"7","author":"J Suskin","year":"2018","unstructured":"Suskin J, Shapiro CL (2018) Osteoporosis and musculoskeletal complications related to therapy of breast cancer. Gland Surg 7:411","journal-title":"Gland Surg"},{"key":"6458_CR20","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/1471-2407-11-384","volume":"11","author":"J-J Body","year":"2011","unstructured":"Body J-J (2011) Increased fracture rate in women with breast cancer: a review of the hidden risk. BMC Cancer 11:384","journal-title":"BMC Cancer"},{"key":"6458_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","volume":"7","author":"P Hadji","year":"2017","unstructured":"Hadji P et al (2017) Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. J Bone Oncol 7:1\u201312","journal-title":"J Bone Oncol"},{"key":"6458_CR22","first-page":"73","volume":"103","author":"Recommendations and Rationale","year":"2003","unstructured":"Recommendations and Rationale (2003) U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women. AJN, American\u202f: Am J Nursing 103:73\u201380","journal-title":"AJN, American : Am J Nursing"},{"key":"6458_CR23","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","volume":"34","author":"DM Reid","year":"2008","unstructured":"Reid DM et al (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 34:S3\u2013S18","journal-title":"Cancer Treat Rev"},{"key":"6458_CR24","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1007\/s00198-011-1870-0","volume":"23","author":"R Rizzoli","year":"2012","unstructured":"Rizzoli R et al (2012) Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int 23:2567\u20132576","journal-title":"Osteoporos Int"},{"key":"6458_CR25","doi-asserted-by":"crossref","unstructured":"Shapiro CL. (2020) Management of osteoporosis in women with breast cancer. Breast Cancer Manag BMT40.","DOI":"10.2217\/bmt-2020-0012"},{"key":"6458_CR26","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s10549-012-2151-0","volume":"134","author":"JA Ligibel","year":"2012","unstructured":"Ligibel JA et al (2012) Patterns of bone density evaluation in a community population treated with aromatase inhibitors. Breast Cancer Res Treat 134:1305\u20131313","journal-title":"Breast Cancer Res Treat"},{"key":"6458_CR27","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/2193-1801-3-328","volume":"3","author":"D L\u00fcftner","year":"2014","unstructured":"L\u00fcftner D et al (2014) Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study. Springerplus 3:328","journal-title":"Springerplus"},{"key":"6458_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","volume":"129","author":"M Yong","year":"2011","unstructured":"Yong M et al (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999\u20132007). Breast Cancer Res Treat 129:495\u2013503","journal-title":"Breast Cancer Res Treat"},{"key":"6458_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12905-021-01430-1","volume":"21","author":"S Bailey","year":"2021","unstructured":"Bailey S, Lin J (2021) The association of osteoporosis knowledge and beliefs with preventive behaviors in postmenopausal breast cancer survivors. BMC Women\u2019s Health 21:1\u20138","journal-title":"BMC Women\u2019s Health"},{"key":"6458_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.breast.2016.10.018","volume":"31","author":"L Bo\u0161kovi\u0107","year":"2017","unstructured":"Bo\u0161kovi\u0107 L et al (2017) Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors. The Breast 31:16\u201319","journal-title":"The Breast"},{"key":"6458_CR31","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1634\/theoncologist.2019-0149","volume":"24","author":"WD Leslie","year":"2019","unstructured":"Leslie WD et al (2019) Fracture risk in women with breast cancer initiating aromatase inhibitor therapy: a registry-based cohort study. Oncologist 24:1432\u20131438","journal-title":"Oncologist"},{"key":"6458_CR32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2104162","volume":"385","author":"M Gnant","year":"2021","unstructured":"Gnant M et al (2021) Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer. N Engl J Med 385:395\u2013405","journal-title":"N Engl J Med"},{"key":"6458_CR33","doi-asserted-by":"publisher","unstructured":"Neuner, J. M. et al. Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy. doi:https:\/\/doi.org\/10.1007\/s11764-017-0666-4.","DOI":"10.1007\/s11764-017-0666-4"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06458-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06458-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06458-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T17:39:47Z","timestamp":1662745187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06458-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["6458"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06458-z","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,14]]},"assertion":[{"value":"3 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}